Neurology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Develop A Family Registry to Collect Alzheimer's Biomarkers

   Jacksonville, Fla.

   The overall purpose of this research is to understand how ADAD develops in order to eventually provide treatments for this disorder. Each biological child of a person with an ADAD mutation has a 50% risk of inheriting the mutation, and thus of developing ADAD. This study will develop a registry of families with a known ADAD mutation and will collect, analyze and bank data, tissue, and brain images from the members who participate in the DIAN research study. The data and tissue collected are available to all qualified researchers who wish to determine what changes occur before and after ADAD symptoms start. This understanding may lead to better tests and treatments for ADAD.

    

2. A Study of the Possible Use of a New Imaging Method with Glioma Tumors

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to see if Magnetic Resonance Elastography (MRE) a recently developed imaging technique can be used to characterize and help stage glioma tumors and evaluate response to therapy.

3. Analyses of Metabolic Agents Following Brain Radiation

   Rochester, Minn.

   The purpose of this study is to determine the feasibility of serial cerebrospinal fluid (CSF) assessments to evaluate the pharmacodynamic impact of agents targeting radiation-induced biology administered following completion of brain radiation.

4. Evaluating Optic Nerve Disease with OCT Angiography

   Rochester, Minn.

   The purpose of this study is to determine if optical coherence tomography (OCT) angiography is able to distinguish different causes of optic neuropathy.

5. Magnetic Resonance Elastography of Traumatic Brain Injury

   Rochester, Minn.

   This purpose of this pilot study is to determine if there are changes in mild TBI detectible with MRE. This is the first time this novel technology has been applied to mild TBI and the anticipated results are theoretical.

6. A Study to Assess Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH)

   Rochester, Minn.

   The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

7. Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

   Rochester, Minn.

   The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

8. A Registry of Biospecimens for Patients with Central Nervous Systems Inflammatory Disease

   Rochester, Minn.

   The purpose of the study is to learn more about inflammatory diseases of the central nervous system (CNS) by collecting patient information, blood sample (which contain a person’s genes, DNA) and other available tissue samples.

9. A Study to Evaluate Biomarker Target Stimulation

   Rochester, Minn.

   The purpose of this study is to understand how electrical stimulation of the brain can modulate and suppress interictal epileptiform activity as a step on the path to developing new therapies for epilepsy.

10. E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

    Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to determine the overall rate of response of brain metastases in subjects with central nervous system (CNS) metastases due to metastatic melanoma with a BRAF V600 mutation who have relapsed or progressed from initial or systemic disease.

    .